4α,5α-epoxy-17β-hydroxy-4β,17α-dimethyl-3-oxoandrostene-2α-carbonitrile | 71507-79-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4α,5α-epoxy-17β-hydroxy-4β,17α-dimethyl-3-oxoandrostene-2α-carbonitrile
• 英文别名: epostane；(2α,4α,5α,17β)-4,5-epoxy-17-hydroxy-4,17-dimethyl-3-oxoandrosta-2-carbonitrile；4α,5α-epoxy-17β-hydroxy-4,17-dimethyl-3-oxoandrostane-2α-carbonitrile；(2alpha,4alpha,5alpha,17beta)-4,5-Epoxy-17-hydroxy-4,17-dimethyl-3-oxoandrosta-2-carbonitrile；(1S,2R,4S,6S,8S,11S,12S,15S,16S)-15-hydroxy-2,6,15,16-tetramethyl-5-oxo-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadecane-4-carbonitrile
• CAS: 71507-79-4
• 化学式: C₂₂H₃₁NO₃
• 分子量: 357.493
• InChiKey: VOPNDTFUMCWVME-PBDUVLNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  73.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  17beta-羟基-4,17-二甲基雄甾-4-烯-3-酮 在 羟胺 、 sodium methylate 、 间氯过氧苯甲酸 作用下， 生成 4α,5α-epoxy-17β-hydroxy-4β,17α-dimethyl-3-oxoandrostene-2α-carbonitrile
  参考文献：
  名称：

  Steroidogenesis inhibitors. 1. Adrenal inhibitory and interceptive activity of trilostane and related compounds

  摘要：

  Several methylated derivatives of trilostane were prepared. Methylation of C-4 or C-4 and C-17 changes this relatively selective adrenal inhibitor to compounds with increased ovarian/placental inhibitory activity with decreased adrenal inhibitory activity.

  DOI：

  10.1021/jm00373a021

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• [EN] PROCESS FOR PREPARING CRYSTALLINE CICLESONIDE WITH DEFINED PARTICLE SIZE<br/>[FR] PROCEDE DE PREPARATION DE CICLESONIDE CRISTALLIN DE GRANULOMETRIE DEFINIE
  申请人：ALTANA PHARMA AG

  公开号：WO2004085460A1

  公开（公告）日：2004-10-07

  The invention relates to a novel process for preparing crystalline ciclesonide with an advantageous particle size and to the use for producing pharmaceutical preparations, in particular for topical use. The crystalline ciclesonide obtained by the novel process has advantageous aerodynamic properties, and can be further processed to inhalable or nasally administered pharmaceutical preparations without further mechanical micronization.

  本发明涉及一种制备晶体环仙酮的新工艺，其具有优越的颗粒大小，并用于制备制药制剂，特别是用于局部使用。通过新工艺获得的晶体环仙酮具有优越的空气动力学性能，并且可以进一步加工成可吸入或鼻腔给药的制药制剂，无需进一步机械微粉化。
• [EN] METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES
  申请人：ENDORECHERCHE INC.

  公开号：WO1991000733A1

  公开（公告）日：1991-01-24

  (EN) A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combination therapy. Sex steroid biosynthesis inhibitors, especially those capable of inhibiting conversion of dehydroepiandrosterone (DHEA) or 4-androstenedione ($g(D)4-dione) to natural sex steroida (and testosterone into dihydrotestosterone) in peripheral tissues, are used in combination with antiandrogens usually after blockade of testicular hormonal secretions. Antiestrogens can also be part of the combination therapy. Pharmaceutical compositions and two, three, four and five component kits are useful for such combination treatment.(FR) Le procédé décrit, qui sert à traiter les maladies associées aux androgènes, tels que les cancers de la prostate, chez des animaux mâles susceptibles de développer de telles pathologies, y compris chez l'homme, consiste à procéder à l'administration de nouveaux anti-androgènes et/ou de nouveaux inhibiteurs de biosynthèse des stéroïdes sexuels, cette administration faisant partie d'une thérapie combinée. Les inhibiteurs de biosynthèse des stéroïdes sexuels, tels qu'en particulier ceux qui sont capables d'inhiber la conversion de déhydroépiandrostéronea (DHEA) ou de 4-androsténedione ($g(D)4-dione) en stéroïdes sexuels naturels (et de testostérone en dihydrotestostérone) dans les tissus périphériques, sont utilisés en combinaison avec des anti-androgènes, habituellement après blocage des sécrétions hormonales testiculaires. L'administration d'anti-÷strogènes peut également faire partie de la thérapie combinée. Des compositions pharmaceutiques et deux, trois, quatre et cinq kits d'éléments utiles dans un tel traitement combiné sont décrits.

  一种治疗雄激素相关疾病的方法，例如易感雄性动物（包括人类）的前列腺癌，包括在组合疗法中给予新型抗雄激素和/或新型性激素合成抑制剂。性激素合成抑制剂，特别是那些能够抑制外周组织中脱氢表雄酮（DHEA）或4-雄烯二酮（$g（D）4-二酮）转化为天然性激素（和睾酮转化为双氢睾酮）的药物，通常在阻断睾丸激素分泌后与抗雄激素联合使用。抗雌激素也可以成为组合疗法的一部分。制药组合物和两个、三个、四个和五个成分的套装对于这种组合治疗非常有用。